ICCM IceCure Medical Ltd.
IceCure Medical Ltd. (ICCM) is confirmed to report earnings on November 18, 2026, before the market open. The consensus earnings estimate is a loss of $0.84 per share.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About IceCure Medical Ltd.
IceCure Medical develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer.
Sector
Healthcare
Industry
Medical Instruments/Supply
Charts powered in part by Lightweight Charts™ by TradingView.